o-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: o-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde
• 英文别名: 2-[2-(5-Ethylpyridin-2-yl)ethoxy]benzaldehyde
• 化学式: C₁₆H₁₇NO₂
• 分子量: 255.316
• InChiKey: ZIEQNJPMEYGDCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,6-二甲氧基茚酮 、 o-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde 在 四氢吡咯 作用下， 以 甲醇 为溶剂， 以57%的产率得到2-[[o-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methylidene]-5,6-dimethoxy-1-indanone
  参考文献：
  名称：

  Design, synthesis, molecular docking, and in vitro antidiabetic activity of novel PPARγ agonist

  摘要：

  The present work describes the design, synthesis, molecular docking, biological evaluation, and assessment of structure-activity relationship of new derivatives based upon the molecular skeleton of the drug pioglitazone, a compound which is currently used for the management of type 2 diabetes mellitus. Pioglitazone has several side effects such as weight gain, edema, congestive heart failure, and bladder cancer. Therefore, there is a strong demand for identification of new lead candidates in the treatment of type 2 diabetes mellitus. A series of 24 compounds were prepared and evaluated for their peroxisome proliferator-activated receptor-gamma (PPAR gamma) binding affinity assay and the IC50 values were determined. Among these compounds, six compounds exhibited promising IC50 values as compared to standard drugs pioglitazone and rosiglitazone. Furthermore, in order to confirm the target of these molecules, molecular docking study was carried out with peroxisome proliferator-activated receptor-gamma (PPAR gamma) protein. Molecular modeling studies suggested that these compounds appropriately interact in the active sites of receptor.[GRAPHICS].

  DOI：

  10.1007/s00706-018-2207-x
• 作为产物：
  描述：

  5-乙基-2-吡啶乙醇 在 potassium carbonate 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 23.0h， 生成 o-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde
  参考文献：
  名称：

  Design, synthesis, molecular docking, and in vitro antidiabetic activity of novel PPARγ agonist

  摘要：

  The present work describes the design, synthesis, molecular docking, biological evaluation, and assessment of structure-activity relationship of new derivatives based upon the molecular skeleton of the drug pioglitazone, a compound which is currently used for the management of type 2 diabetes mellitus. Pioglitazone has several side effects such as weight gain, edema, congestive heart failure, and bladder cancer. Therefore, there is a strong demand for identification of new lead candidates in the treatment of type 2 diabetes mellitus. A series of 24 compounds were prepared and evaluated for their peroxisome proliferator-activated receptor-gamma (PPAR gamma) binding affinity assay and the IC50 values were determined. Among these compounds, six compounds exhibited promising IC50 values as compared to standard drugs pioglitazone and rosiglitazone. Furthermore, in order to confirm the target of these molecules, molecular docking study was carried out with peroxisome proliferator-activated receptor-gamma (PPAR gamma) protein. Molecular modeling studies suggested that these compounds appropriately interact in the active sites of receptor.[GRAPHICS].

  DOI：

  10.1007/s00706-018-2207-x

文献信息

• US5952509A
  申请人：——

  公开号：US5952509A

  公开（公告）日：1999-09-14
• Design, synthesis, molecular docking, and in vitro antidiabetic activity of novel PPARγ agonist
  作者：Radha Nandan Chaturvedi、Krishnaiah Pendem、Vipul P. Patel、Mukta Sharma、Sunita Malhotra

  DOI：10.1007/s00706-018-2207-x

  日期：2018.11

  The present work describes the design, synthesis, molecular docking, biological evaluation, and assessment of structure-activity relationship of new derivatives based upon the molecular skeleton of the drug pioglitazone, a compound which is currently used for the management of type 2 diabetes mellitus. Pioglitazone has several side effects such as weight gain, edema, congestive heart failure, and bladder cancer. Therefore, there is a strong demand for identification of new lead candidates in the treatment of type 2 diabetes mellitus. A series of 24 compounds were prepared and evaluated for their peroxisome proliferator-activated receptor-gamma (PPAR gamma) binding affinity assay and the IC50 values were determined. Among these compounds, six compounds exhibited promising IC50 values as compared to standard drugs pioglitazone and rosiglitazone. Furthermore, in order to confirm the target of these molecules, molecular docking study was carried out with peroxisome proliferator-activated receptor-gamma (PPAR gamma) protein. Molecular modeling studies suggested that these compounds appropriately interact in the active sites of receptor.[GRAPHICS].